|
1.Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2:675-680. 2.Medzhitov, R., P. Preston-Hurlburt, and C. A. Janeway, Jr. 1997. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388:394-397. 3.Lemaitre, B., E. Nicolas, L. Michaut, J. M. Reichhart, and J. A. Hoffmann. 1996. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86:973-983. 4.Yamamoto, M., and K. Takeda. 2010. Current views of toll-like receptor signaling pathways. Gastroenterol Res Pract 2010:240365. 5.Jin, M. S., and J. O. Lee. 2008. Structures of the toll-like receptor family and its ligand complexes. Immunity 29:182-191. 6.Akira, S. 2001. Toll-like receptors and innate immunity. Adv Immunol 78:1-56. 7.Gautam, J. K., Ashish, L. D. Comeau, J. K. Krueger, and M. F. Smith, Jr. 2006. Structural and functional evidence for the role of the TLR2 DD loop in TLR1/TLR2 heterodimerization and signaling. J Biol Chem 281:30132-30142. 8.Dolan, J., K. Walshe, S. Alsbury, K. Hokamp, S. O'Keeffe, T. Okafuji, S. F. Miller, G. Tear, and K. J. Mitchell. 2007. The extracellular leucine-rich repeat superfamily; a comparative survey and analysis of evolutionary relationships and expression patterns. BMC Genomics 8:320. 9.Slack, J. L., K. Schooley, T. P. Bonnert, J. L. Mitcham, E. E. Qwarnstrom, J. E. Sims, and S. K. Dower. 2000. Identification of two major sites in the type I interleukin-1 receptor cytoplasmic region responsible for coupling to pro-inflammatory signaling pathways. J Biol Chem 275:4670-4678. 10.Underhill, D. M., A. Ozinsky, A. M. Hajjar, A. Stevens, C. B. Wilson, M. Bassetti, and A. Aderem. 1999. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 401:811-815. 11.Xu, Y., X. Tao, B. Shen, T. Horng, R. Medzhitov, J. L. Manley, and L. Tong. 2000. Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature 408:111-115. 12.Tabeta, K., K. Hoebe, E. M. Janssen, X. Du, P. Georgel, K. Crozat, S. Mudd, N. Mann, S. Sovath, J. Goode, L. Shamel, A. A. Herskovits, D. A. Portnoy, M. Cooke, L. M. Tarantino, T. Wiltshire, B. E. Steinberg, S. Grinstein, and B. Beutler. 2006. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 7:156-164. 13.Kawai, T., and S. Akira. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:373-384. 14.Kang, J. Y., X. Nan, M. S. Jin, S. J. Youn, Y. H. Ryu, S. Mah, S. H. Han, H. Lee, S. G. Paik, and J. O. Lee. 2009. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 31:873-884. 15.Hasan, U., C. Chaffois, C. Gaillard, V. Saulnier, E. Merck, S. Tancredi, C. Guiet, F. Briere, J. Vlach, S. Lebecque, G. Trinchieri, and E. E. Bates. 2005. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 174:2942-2950. 16.Jin, M. S., S. E. Kim, J. Y. Heo, M. E. Lee, H. M. Kim, S. G. Paik, H. Lee, and J. O. Lee. 2007. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130:1071-1082. 17.Ozinsky, A., D. M. Underhill, J. D. Fontenot, A. M. Hajjar, K. D. Smith, C. B. Wilson, L. Schroeder, and A. Aderem. 2000. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A 97:13766-13771. 18.Underhill, D. M., A. Ozinsky, K. D. Smith, and A. Aderem. 1999. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci U S A 96:14459-14463. 19.Kawai, T., O. Adachi, T. Ogawa, K. Takeda, and S. Akira. 1999. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11:115-122. 20.Horng, T., G. M. Barton, R. A. Flavell, and R. Medzhitov. 2002. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 420:329-333. 21.Kyriakis, J. M., and J. Avruch. 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81:807-869. 22.Wang, C., L. Deng, M. Hong, G. R. Akkaraju, J. Inoue, and Z. J. Chen. 2001. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412:346-351. 23.Chang, L., and M. Karin. 2001. Mammalian MAP kinase signalling cascades. Nature 410:37-40. 24.Sancho, R., A. S. Nateri, A. G. de Vinuesa, C. Aguilera, E. Nye, B. Spencer-Dene, and A. Behrens. 2009. JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J 28:1843-1854. 25.Treinies, I., H. F. Paterson, S. Hooper, R. Wilson, and C. J. Marshall. 1999. Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal To stimulate DNA synthesis. Mol Cell Biol 19:321-329. 26.Chen, Z. J. 2005. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 7:758-765. 27.Deng, L., C. Wang, E. Spencer, L. Yang, A. Braun, J. You, C. Slaughter, C. Pickart, and Z. J. Chen. 2000. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103:351-361. 28.Jenkins, K. A., and A. Mansell. 2010. TIR-containing adaptors in Toll-like receptor signalling. Cytokine 49:237-244. 29.Ghosh, S., and M. Karin. 2002. Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl:S81-96. 30.Hansson, G. K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-1695. 31.Janeway, C. A., Jr., and R. Medzhitov. 2002. Innate immune recognition. Annu Rev Immunol 20:197-216. 32.Simionescu, M. 2007. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol 27:266-274. 33.Jonasson, L., J. Holm, O. Skalli, G. Gabbiani, and G. K. Hansson. 1985. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest 76:125-131. 34.Yan, Z. Q., and G. K. Hansson. 2007. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 219:187-203. 35.1998. Inflammatory and Immune Mechanisms in Vascular Disease. Bethesda, Maryland, USA. February 19-20, 1998. Abstracts. J Vasc Surg 27:1152-1192. 36.Mullick, A. E., P. S. Tobias, and L. K. Curtiss. 2005. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 115:3149-3156. 37.Kazemi, M. R., C. M. McDonald, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 2005. Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler Thromb Vasc Biol 25:1220-1224. 38.Makowski, L., J. B. Boord, K. Maeda, V. R. Babaev, K. T. Uysal, M. A. Morgan, R. A. Parker, J. Suttles, S. Fazio, G. S. Hotamisligil, and M. F. Linton. 2001. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 7:699-705. 39.Davies, M. J., J. L. Gordon, A. J. Gearing, R. Pigott, N. Woolf, D. Katz, and A. Kyriakopoulos. 1993. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 171:223-229. 40.Liu, X., T. Ukai, H. Yumoto, M. Davey, S. Goswami, F. C. Gibson, 3rd, and C. A. Genco. 2008. Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis 196:146-154. 41.Nilsson, L. M., Z. W. Sun, J. Nilsson, I. Nordstrom, Y. W. Chen, J. D. Molkentin, D. Wide-Swensson, P. Hellstrand, M. L. Lydrup, and M. F. Gomez. 2007. Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation. Am J Physiol Cell Physiol 292:C1167-1178. 42.Grassl, C., B. Luckow, D. Schlondorff, and U. Dendorfer. 1999. Transcriptional regulation of the interleukin-6 gene in mesangial cells. J Am Soc Nephrol 10:1466-1477. 43.Wang, D., Z. Liu, Q. Li, M. Karpurapu, V. Kundumani-Sridharan, H. Cao, N. Dronadula, F. Rizvi, A. K. Bajpai, C. Zhang, G. Muller-Newen, K. W. Harris, and G. N. Rao. 2007. An essential role for gp130 in neointima formation following arterial injury. Circ Res 100:807-816. 44.Schindler, U., and V. R. Baichwal. 1994. Three NF-kappa B binding sites in the human E-selectin gene required for maximal tumor necrosis factor alpha-induced expression. Mol Cell Biol 14:5820-5831. 45.Ohbayashi, N., O. Ikeda, N. Taira, Y. Yamamoto, R. Muromoto, Y. Sekine, K. Sugiyama, T. Honjoh, and T. Matsuda. 2007. LIF- and IL-6-induced acetylation of STAT3 at Lys-685 through PI3K/Akt activation. Biol Pharm Bull 30:1860-1864. 46.Martin, M., K. Rehani, R. S. Jope, and S. M. Michalek. 2005. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6:777-784. 47.Martin, M., R. E. Schifferle, N. Cuesta, S. N. Vogel, J. Katz, and S. M. Michalek. 2003. Role of the phosphatidylinositol 3 kinase-Akt pathway in the regulation of IL-10 and IL-12 by Porphyromonas gingivalis lipopolysaccharide. J Immunol 171:717-725. 48.Salaun, B., P. Romero, and S. Lebecque. 2007. Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol 37:3311-3318. 49.Kavurma, M. M., and L. M. Khachigian. 2003. ERK, JNK, and p38 MAP kinases differentially regulate proliferation and migration of phenotypically distinct smooth muscle cell subtypes. J Cell Biochem 89:289-300. 50.Bhoumik, A., and Z. Ronai. 2008. ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle 7:2341-2345. 51.Salameh, A., F. Galvagni, F. Anselmi, C. De Clemente, M. Orlandini, and S. Oliviero. 2010. Growth factor stimulation induces cell survival by c-Jun. ATF2-dependent activation of Bcl-XL. J Biol Chem 285:23096-23104. 52.Hai, T., and M. G. Hartman. 2001. The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene 273:1-11. 53.Ma, Q., X. Li, D. Vale-Cruz, M. L. Brown, F. Beier, and P. LuValle. 2007. Activating transcription factor 2 controls Bcl-2 promoter activity in growth plate chondrocytes. J Cell Biochem 101:477-487. 54.Medzhitov, R., and T. Horng. 2009. Transcriptional control of the inflammatory response. Nat Rev Immunol 9:692-703. 55.Ghosh, S., and M. S. Hayden. 2008. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 8:837-848. 56.Ollivier, V., G. C. Parry, R. R. Cobb, D. de Prost, and N. Mackman. 1996. Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem 271:20828-20835. 57.Parry, G. C., and N. Mackman. 1997. Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. J Immunol 159:5450-5456. 58.Burleigh, M. E., V. R. Babaev, P. G. Yancey, A. S. Major, J. L. McCaleb, J. A. Oates, J. D. Morrow, S. Fazio, and M. F. Linton. 2005. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol 39:443-452. 59.Fukata, M., A. Chen, A. Klepper, S. Krishnareddy, A. S. Vamadevan, L. S. Thomas, R. Xu, H. Inoue, M. Arditi, A. J. Dannenberg, and M. T. Abreu. 2006. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology 131:862-877. 60.Krishnan, J., K. Selvarajoo, M. Tsuchiya, G. Lee, and S. Choi. 2007. Toll-like receptor signal transduction. Exp Mol Med 39:421-438. 61.Cole, J. E., E. Georgiou, and C. Monaco. 2010. The expression and functions of toll-like receptors in atherosclerosis. Mediators Inflamm 2010:393946. 62.Huang, G., L. Z. Shi, and H. Chi. 2009. Regulation of JNK and p38 MAPK in the immune system: signal integration, propagation and termination. Cytokine 48:161-169.
|